摘要
目的探讨血清癌胚抗原（CEA）、糖类抗原50（CA50）、细胞角质蛋白（CYFRA21—1）、鳞状细胞癌抗原（SCC）和神经烯醇化酶（NSE）对晚期肺癌化疗疗效及进展评估的意义。方法分别采取2008～2012年确诊的肺癌（Ⅲb～Ⅳ期）患者的化疗前、缓解及进展时的血清标本，检测每份血清标本CEA、CA50、CYFRA21-1、SCC和NSE5种肿瘤标记物，比较它们之间的差异及探讨其与不同病理类型的晚期肺癌化疗疗效的关系。结果综合考虑疗效与病理类型两方面影响因素，CEA、CA50、CYFRA21-1、SCC和NSE的数值变化差异均有统计学意义（PCEA=0．034、PCA50=0．003、PCYFRA21-=0．039、PSCC=0．019和PNSE=0．000），且CEA及CA50数值变化在肺腺癌组最为明显，CYFRA21-1及SCC数值变化在肺鳞癌组最为明显，NSE数值变化在肺小细胞癌组最为明显。结论肿瘤标志物CEA、CA50、CYFRA21-1、SCC和NSE可分别作为晚期肺腺癌、鳞癌及小细胞癌的化疗疗效及进展评估的重要指标。
Objective To investigate the significance of cancer embryonic antigen（CEA） ,carbohydrate antigen 50 （CA50）, cytokaratin（CYFRA21-1）, squamous cell cancer antigen（SCC） and neuron specific enolase（NSE） on the chemotherapy efficacy and the progress evaluation in advanced lung cancer. Methods The serum samples were col- lected before chemotherapy,in remission and progression from the patients diagnosed with advanced lung cancer（IIIb- IV） during 2008-2012. Each sample was detected the five tumor markers CEA, CA50, CYFRA21-1, SCC and NSE. The differences among them were compared and their relationship with chemotherapy efficacy in different pathologi cal types of advanced lung cancer was investigated. Results Considering the influencing factors of efficacy and patho- logical types,the differences of CEA, CA50, CYFRA21-1, SCC and NSE values had statistical significance （PCEA = 0. 034, PCA50= 0. 003, PCYSRA21, = 0. 039, Pscc = 0. 019 and PNSE = 0. 000）. The changes of CEA and CA50 values were most obvious in the lung adenocarcinoma group,which of CYFRA21-1 and SCC value were most evident in the lung squamous cell carcinoma group and which of NSE value were most pronounced in the small cell carcinoma of lung group. Conclusion The tumor markers of CEA,CA50,CYFRA21-1 ,SCC and NSE could be used as the important in- dicators for the evaluation of chemotherapy efficacy and progress in advanced lung adenocarcinoma, squamous cell carcinoma and small cell carcinoma.
出处
《检验医学与临床》
CAS
2014年第2期183-185,共3页
Laboratory Medicine and Clinic
